{"filing":{"accession_number":"0001654954-26-007983","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"a7347s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007983/a7347s.htm"},"events":[{"id":30772,"run_id":28210,"accession_number":"0001654954-26-007983","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This 6-K furnishes a press release announcing positive Phase III trial results for Tagrisso plus Orpathys in first-line EGFRm lung cancer (SANOVO trial). The disclosure reports statistically significant and clinically meaningful improvement in progression-free survival, a key efficacy endpoint. While technically a clinical trial result rather than financial earnings, this is material to investors as it represents a significant clinical milestone for a major oncology combination therapy that could expand market opportunity and support future revenue growth for AstraZeneca's lung cancer franchise.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33478,"accession_number":"0001654954-26-007983","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This 6-K furnishes a press release announcing positive Phase III trial results for Tagrisso plus Orpathys in first-line EGFRm lung cancer (SANOVO trial). The disclosure reports statistically significant and clinically meaningful improvement in progression-free survival, a key efficacy endpoint. While technically a clinical trial result rather than financial earnings, this is material to investors as it represents a significant clinical milestone for a major oncology combination therapy that could expand market opportunity and support future revenue growth for AstraZeneca's lung cancer franchise.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:04:48.383067+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01"}]}